SYS-CON MEDIA Authors: Sematext Blog, Yeshim Deniz, Elizabeth White, Jason Bloomberg, Liz McMillan

News Feed Item

Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024

NEW YORK, Feb. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024

http://www.reportlinker.com/p02006104/Bleeding-Disorders-World-Pharmaceu...

Report Details

Treating abnormal bleeding - this new report shows you trends, R&D outlooks, and sales forecasts

Treatments for bleeding - what're their prospects? Visiongain's new report gives you predictions for drugs controlling those blood clotting diseases. Stay ahead then. You discover financial results, technologies, R&D trends, opportunities, and forecasted revenues.

So you see what's possible for treating haemophilia (hemophilia) and other blood-coagulation disorders. Avoid missing out. You get data and analysis for that industry and market, assessing outlooks. You find business analysis, progress, and potential gains.

Hear what lies ahead for those products, benefiting your work and influence. Read on, then, to explore those medicines and see what their future could be worth.

Forecasts and other information explaining lucrative possibilities for treatments

Our study reveals trade predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials.

Besides revenue forecasting from 2013 to 2024, that new work shows historical findings, growth rates, and market shares. There you get feel for commercial outlooks and developments (R&D). You also gain an interview, 50 charts, and 78 tables.

Futures of medicines stopping and preventing haemorrhaging - data to help your work

Our study concludes that, from 2014, patients, healthcare providers, and pharma companies will gain from that medical and technological progress. Hear what's possible.

Find there how you can help your research, analyses, and decisions. Also save time. And discover how you could benefit your authority through better understanding the future.

So the following sections explain what you get in our new investigation.

Forecasting of that world market and its main segments - see what's likely to happen

What's that industry's potential? What're the secrets of its progress? Discover in our report overall world revenue to 2024 for pharmaceuticals controlling bleeding.

Also you see individual revenue predictions to 2024 for four therapeutic submarkets at world level:

• Haemophilia A

• Haemophilia B

• Thrombocytopenia

• Related diseases (other coagulation factor deficiencies, grouped).

How will those markets expand? Which classes of therapy will generate most money? So you assess outlooks for sales growth, seeing where you can gain.

There you explore competition and rising sales. Also you assess products' futures.

Predicting of existing and expected therapies' revenues

Find sales outlooks for top brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for 10 marketed products, including these:

• Advate

• NovoSeven

• Kogenate

• BeneFIX

• FEIBA.

You also get revenue predictions for five expected agents, including these:• Rixubis• Eloctate• Alprolix.

There you find drugs and years with highest predicted sales rises. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and successes.

Our work also divides its overall prediction into geographical regions.

Healthcare in national markets - what outlooks for business?

In developed and developing countries, opportunities for providers of those products and technologies will occur from 2014 to 2024. See where and how, finding sales potentials.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:

United States (US)

Japan

Germany, France, UK, Italy, and Spain (EU5)

Brazil, Russia, India, and China (BRIC nations).

There you find places with highest revenues and potential sales growth. Our work explains. You assess international prospects for modifying bleeding control, preventing excessive blood loss, also appraising needs and demands.

Explore, too, how that haematological technology benefits developers, producers, marketers, and sellers. Our work shows you, discussing issues.

Events and forces for developing, producing, marketing, and selling blood-stemming drugs

The report shows you issues and events affecting that industry from 2014, including these:

• Advances in understanding haemostasis and coagulation aiding science and product development

• Needle-free drug delivery and other innovations

• Synthetic purification processes and other novel techniques for making biologics and biosimilars

• Long-acting clotting factor therapy and recombinant coagulation factors

• Use of prophylactic schedules (prophylaxis) increasing

• Regulators, pricing, and other challenges - approvals, costs, and concerns.

There you explore political, economic, social, and technological questions, investigating outlooks for business. Discover what the future holds.

Examine, then, what stimulates and restrains players in that industry and affects results.

Companies and overall 2017 market value - find outlook for success

What happens next? From 2014 new treatments there and improving healthcare in rising countries encourage investments, medical advances, and higher revenues.

So our report predicts the world drugs market for preventing haemorrhages will generate $13.5bn in 2017. There, large medical firms and biopharma specialists can win. See how.

In particular, then, you explore activities and prospects of these companies:

• Baxter

• Novo Nordisk

• Bayer

• Pfizer

• CSL Behring.

R&D in that industry holds strengths, and from 2014 there will arise many opportunities. This decade onwards, then, patients, payers, and companies will benefit.

And you discover how that market can perform, staying ahead in knowledge.

Ways Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024 helps

In particular, our new investigation gives you these advantages:

• Revenues there to 2024 at world level, for 4 submarkets, and 15 products - assess outlooks for production, marketing, and sales

• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - examine developed and developing countries for potential revenues

• Prospects for established competitors, emerging companies, and new entrants - investigate portfolios, results, strategies, developmental activities, and successes.

Information found nowhere else, helping your searches, analyses, and decisions

Our new study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore commercial possibilities.

With that data you're less likely to fall behind in information or miss opportunity. Being free to choose, you find how you could save time and effort with our study, aiding your decisions.

You discover original insights then. So act now in advance of your rivals, also benefiting your authority.

1. Executive Summary

1.1 What This Report Covers1.2 Bleeding Disorders: World Pharma Industry and Market Overview 2013-20241.3 Chapter Outlines1.4 Research and Analysis Methods

2. Introduction to Bleeding Disorders

2.1 Understanding Haemostasis and Coagulation2.1.1 Vascular Spasm2.1.2 Platelet Activation and Aggregation2.1.3 Coagulation2.2 An Introduction to the Bleeding Disorders and Their Treatment2.2.1 Haemophilia A, B and C2.2.2 Von Willebrand Disease2.2.3 Thrombocytopenia

3. The World Pharmaceutical Market for Bleeding Disorders 2014-2024

3.1 The World Pharmaceutical Market for Bleeding Disorders in 20123.2 The Bleeding Disorders Pharmaceutical Market: An Overarching Revenue Forecast 2014-20243.3 The Pharmaceutical Market by Bleeding Disorder: Comparison of Revenue and Market Share, 2018 and 20243.4 The World Pharmaceutical Market for Bleeding Disorders by Therapeutic Subclass: Grouped Revenue Forecasts 2014-20243.5 Haemophilia A Accounted for Almost 70% of the Market in 20123.6 Haemophilia B Will See Increasing Prominence in the Bleeding Disorders Market3.7 Thrombocytopenia3.8 Other Coagulation Factor Deficiencies3.9 Summary of the Research and Analyses

4. Leading Drugs of the Market for Treating Bleeding Disorders, 2014-2024

4.1 The Leading Drugs for the Treatment of Bleeding Disorders in 20124.2 Leading Bleeding Disorder Drugs: Comparison of Revenue and Market Share, 2018 and 20244.3 Leading Bleeding Disorder Drugs: A Grouped Revenue Forecast, 2014-20244.4 Advate Will Continue to Dominate the Market4.5 NovoSeven: Patent Protection Has Expired, But Revenue Generation Remains Strong4.6 Kogenate: Needle-Free Delivery Makes it an Attractive Option for Patients4.7 BeneFIX Faces Competition in 2013 - How Will This Affect Revenue?4.8 FEIBA: The Original Treatment for Disease with Inhibitors4.9 ReFacto/ Xyntha: Produced Using an Entirely Synthetic Purification Process4.10 Helixate: Marketing Agreement With Bayer Extends Until 20174.11 Nplate: The Leading Product for Thrombocytopenia in 20124.12 Alphanate: A Staple Treatment for Bleeding Disorders Since 19784.13 Promacta Competes With Nplate, But Which Will Prove Most Successful?4.14 Promising Compounds in the Developmental Pipeline4.14.1 Rixubis: The First Recombinant FIX Treatment Factor for Routine Prophylaxis in Haemophilia B4.14.2 Eloctate: The First Long-Acting Clotting Factor Therapy for Haemophilia A?4.14.3 Alprolix: The First Long-Acting Clotting Factor Treatment for Haemophilia B?4.14.4 N8-GP: Novo Nordisk's Long Acting Compound for the Treatment of Haemophilia A4.14.5 N9-GP: Novo Nordisk's Long-Acting Treatment for Haemophilia B

5. The Leading National Pharmaceutical Markets for Bleeding Disorders, 2014-2024

5.1 The Leading National Markets for Bleeding Disorders: The US Dominates in 20125.2 The Leading National Markets: Comparison of Revenue and Market Share, 2018 and 20245.3 Leading National Pharmaceutical Markets for Bleeding Disorders: Grouped Revenue Forecasts, 2014-20245.4 The US Will Continue to Dominate the Bleeding Disorders Market Throughout the Forecast Period5.5 The EU5: What Prospects There?5.5.1 Germany Will Remain the Largest of the EU5 Markets5.5.2 France: Increasing Uptake of Prophylactic Therapy Will Drive Growth5.5.3 Italy: The 3rd Largest Market of the EU55.5.4 The UK: Well Developed Infrastructure for the Treatment of Bleeding Disorders5.5.5 Spain: Use of Recombinant Coagulation Factors is Relatively Low at Present5.6 Japan: Use of Prophylactic Treatment is Lower Than That of the Western World5.7 China: A Growing Domestic Bleeding Disorders Pharmaceutical Market5.8 Brazil: Baxter Will Be the Exclusive Provider of Recombinant Therapy for the Next 10 Years5.9 India: 90% of Patients Are Unable to Afford Treatment Costs5.10 Russia: Treatment Levels Per Capita Are High

6. Bleeding Disorders: R&D Pipelines, 2013

6.1 The R&D Pipeline for Bleeding Disorders: An Overview6.2 Four Candidates Are In Pre-Registration6.2.1 Novo Nordisk's NovoEight6.2.2 Novo Nordisk's NovoThirteen: Denied Approval by the FDA for the Second Time; Will It Be Third Time Lucky?6.2.3 Biogen Idec's Eloctate: The First Long-Acting Treatment for Haemophilia A?6.2.4 Biogen Idec's Alprolix: The First Long-Acting Treatment for Haemophilia B?6.3 The Phase III Development Pipeline: Novo Nordisk Has a Strong Presence6.3.1 Novo Nordisk's N8-GP and N9-GP: Second in Class Treatments?6.3.2 Baxter's rFVIIa BI6.3.3 Octapharma's Human-cl rhFVIII6.4 The Phase II/III Development Pipeline: An Abundance of Haemophilia A Treatments6.4.1 Baxter's BAX855: Another Long-Acting Haemophilia A Treatment6.4.2 Baxter has Purchased OBI-1 from Inspiration Biopharmaceuticals6.5 The Phase I/II Development Pipeline: Gene Therapy for Haemophilia B6.6 The Phase I Development Pipeline: Offerings from Novo Nordisk and Pfizer6.6.1 Novo Nordisk's mAb20216.6.2 Pfizer's PF-05280602

7. Leading Companies of the Bleeding Disorders Pharmaceutical Market

7.1 The Leading Companies of the Bleeding Disorders Pharmaceutical Market7.2 Baxter Accounted for Over 30% of the Bleeding Disorders Market in 2012, But Will It Remain Market Leader?7.3 Novo Nordisk: Demonstrating Commitment to Treating Bleeding Disorders7.4 Bayer: A Limited Product Portfolio?7.5 Pfizer: Declining Market Share During the Forecast Period?7.6 CSL Behring Has the largest Portfolio of Bleeding Disorder Drugs7.7 Grifols Will Have a Declining Market Share7.8 Amgen: Single Stake in the Bleeding Disorders Market7.9 Octapharma: Branching Into Recombinant Coagulation Factors7.10 GSK: Bleeding Disorders Are Not a Main Therapeutic Focus7.11 Biogen Idec: Market Entry Anticipated in 2014

8. Qualitative Analysis of the Bleeding Disorders Pharmaceutical Market, 2013-2024

8.1 Strengths and Weaknesses of the Bleeding Disorders Pharmaceutical Market, 20138.1.1 Treatment of Bleeding is Essential8.1.2 The Threat of Generic/Biosimilar Competition is Low8.1.3 Advances in Technology Have Improved Treatment Options8.1.4 A Small Patient Population Ultimately Restricts the Market8.1.5 Emerging National Markets: Patients Often Having Little Access to Treatments8.1.6 High Barriers to Market Entry8.1.7 The Burden of Prophylactic Therapy8.2 The Opportunities and Threats Facing the Market, 2014-20248.2.1 Low Switch Rate Among Patients Receiving Treatment for Bleeding Disorders: An Opportunity and a Threat8.2.2 Demand for Treatment in the Emerging Markets is Increases, But Are Recombinant Therapies Too Expensive?8.2.3 High Barriers to Market Entry Will Limit Competition, But Also Limit Development8.3 Social, Technological, Economic and Political Forces Influencing the Bleeding Disorders Pharmaceutical Market, 2014-20248.3.1 Social Factors8.3.2 Technological Factors8.3.3 Economic Factors8.3.4 Political Factors

9. Research Interview

9.1 Interview With Dr Kamran Kamyar, M.D., Medical Manager, AryoGen Biopharma9.1.1 On the State of the Current Market9.1.2 On AryoGen's Presence in the Market9.1.3 On Important Developments in the Industry

10. Conclusions from Our Study

10.1 The World Pharmaceutical Market for Bleeding Disorders, 2014-202410.2 Bleeding Disorders: Leading Products on the Market, 2014-202410.3 Leading National Markets for the Bleeding Disorder Pharmaceutical Industry, 2014-202410.4 Trends in that Industry and Market10.4.1 Bleeding Disorders Are Serious Conditions Requiring Frequent Drug Treatment10.4.2 The Demand for Drug Treatment Is Increasing10.4.3 The R&D Pipeline is Well Stocked, But What Does This Mean for the Industry?

List of Tables

Table 1.1 Currency Exchange RatesTable 2.1 The Coagulation Factors: Compound Name, Associated Bleeding Disorder and Bleeding SeverityTable 2.2 Treatment for VWD: Drug, Mechanism of Action and Disease TypeTable 3.1 The World Pharmaceutical Market for Bleeding Disorders by Disorder: Revenues ($m) and Market Shares (%), 2012Table 3.2 The Pharmaceutical Market for Bleeding Disorders: Overarching Revenue Forecast ($m), 2013-2024Table 3.3 The World Market by Bleeding Disorder: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024Table 3.4 The World Market for Bleeding Disorders by Disorder: Grouped Revenue ($m) and Market Share (%) Forecasts, 2013-2024Table 3.5 Haemophilia A: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 3.6 Haemophilia B: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 3.7 Thrombocytopenia: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 3.8 Other Coagulation Factor Deficiencies: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.1 The Leading Drugs of the Bleeding Disorders Pharmaceutical Market: Revenues ($m) and Market Shares (%), 2012Table 4.2 The Leading Drugs for the Bleeding Disorders: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024Table 4.3 Leading Drugs: Grouped Revenue Forecasts ($m), 2013-2024Table 4.4 Advate: Key FactsTable 4.5 Advate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.6 NovoSeven: Key FactsTable 4.7 NovoSeven: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.8 Kogenate: Key FactsTable 4.9 Kogenate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.10 BeneFIX: Key FactsTable 4.11 BeneFIX: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.12 FEIBA: Key FactsTable 4.13 FEIBA: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.14 ReFacto/ Xyntha: Key FactsTable 4.15 ReFacto/ Xyntha: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.16 Helixate: Key FactsTable 4.17 Helixate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.18 Nplate: Key FactsTable 4.19 Nplate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.20 Alphanate: Key FactsTable 4.21 Alphanate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.22 Promacta: Key FactsTable 4.23 Promacta: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.24 Rixubis: Key FactsTable 4.25 Rixubis: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.26 Eloctate: Key FactsTable 4.27 Eloctate: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.28 Alprolix: Key FactsTable 4.29 Alprolix: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.30 N8-GP: Key FactsTable 4.31 N8-GP: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 4.32 N9-GP: Key FactsTable 4.33 N9-GP: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.1 Leading National Markets for Bleeding Disorders: Revenues ($m) and Market Shares (%), 2012Table 5.2 The Leading National Markets: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024Table 5.3 The Leading National Markets for Bleeding Disorders: Grouped Revenue Forecasts ($m), 2013-2024Table 5.4 The US Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.5 The EU5 Bleeding Disorders Market by Country: Revenue ($m) and Market Share (%) Forecasts, 2013-2024Table 5.6 The German Bleeding Disorder Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.7 The French Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.8 The Italian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.9 The UK Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.10 The Spanish Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.11 The Japanese Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.12 The Chinese Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.13 The Brazilian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.14 The Indian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 5.15 The Russian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024Table 6.1 Bleeding Disorders: Candidates in Pre-Registration, 2013Table 6.2 Bleeding Disorders: Candidates in Phase III Development, 2013Table 6.3 Bleeding Disorders: Candidates in Phase II/III Development, 2013Table 6.4 Bleeding Disorders: Candidates in Phase I/II Development, 2013Table 6.5 Bleeding Disorders: Candidates in Phase I Development, 2013Table 7.1 The Leading Companies of the Bleeding Disorders Market: Revenues ($m) and Market Shares (%), 2012Table 7.2 Baxter: Product Portfolio for Bleeding Disorders, 2013Table 7.3 Novo Nordisk: Bleeding Disorders Product Portfolio, 2013Table 7.4 Bayer: Bleeding Disorders Product Portfolio, 2013Table 7.5 Pfizer: Bleeding Disorders Product Portfolio, 2013Table 7.6 CSL Behring: Bleeding Disorders Product Portfolio, 2013Table 7.7 Grifols: Bleeding Disorders Product Portfolio, 2013Table 7.8 Amgen: Bleeding Disorders Product Portfolio, 2013Table 7.9 Octapharma: Bleeding Disorders Product Portfolio, 2013Table 7.10 GlaxoSmithKline: Bleeding Disorders Product Portfolio, 2013Table 7.11 Biogen Idec: Bleeding Disorders Product Portfolio, 2013Table 8.1 Strengths and Weaknesses of the Bleeding Disorders Pharmaceutical Market, 2013Table 8.2 Opportunities and Threats Facing the Bleeding Disorders Pharmaceutical Market, 2013-2024Table 8.3 Social, Technological, Economic and Political Factors Influencing the Bleeding Disorders Market (STEP Analysis), 2013-2024

List of Figures

Figure 2.1 Diagram of the Coagulation CascadeFigure 3.1 The World Pharmaceutical Market for Bleeding Disorders by Disorder: Market Shares (%), 2012Figure 3.2 The Pharmaceutical Market for Bleeding Disorders: Overarching Revenue Forecast ($m), 2013-2024Figure 3.3 The World Market by Bleeding Disorder: Market Shares (%), 2018Figure 3.4 The World Market by Bleeding Disorder: Market Shares (%), 2024Figure 3.5 Haemophilia A: Revenue Forecast ($m), 2013-2024Figure 3.6 The Haemophilia A Submarket: Driving and Restraining Factors, 2013Figure 3.7 Haemophilia B: Revenue Forecast ($m), 2013-2024Figure 3.8 The Haemophilia B Submarket: Driving and Restraining Factors, 2013Figure 3.9 Thrombocytopenia: Revenue Forecast ($m), 2013-2024Figure 3.10 The Thrombocytopenia Submarket: Driving and Restraining Factors, 2013Figure 3.11 Other Coagulation Factor Deficiencies: Revenue Forecast ($m), 2013-2024Figure 4.1 Leading Drugs of the Bleeding Disorders Pharmaceutical Market: Market Shares (%), 2012Figure 4.2 Leading Drugs for Bleeding Disorders: Market Shares (%), 2018Figure 4.3 Leading Drugs for Bleeding Disorders: Market Shares (%), 2024Figure 4.4 Advate: Revenue Forecast ($m), 2013-2024Figure 4.5 NovoSeven: Revenue Forecast ($m), 2013-2024Figure 4.6 Kogenate: Revenue Forecast ($m), 2013-2024Figure 4.7 BeneFIX: Revenue Forecast ($m), 2013-2024Figure 4.8 FEIBA: Revenue Forecast ($m), 2013-2024Figure 4.9 ReFacto/ Xyntha: Revenue Forecast ($m), 2013-2024Figure 4.10 Helixate: Revenue Forecast ($m), 2013-2024Figure 4.11 Nplate: Revenue Forecast ($m), 2013-2024Figure 4.12 Alphanate: Revenue Forecast ($m), 2013-2024Figure 4.13 Promacta: Revenue Forecast ($m), 2013-2024Figure 4.14 Rixubis: Revenue Forecast ($m), 2013-2024Figure 4.15 Eloctate: Revenue Forecast ($m), 2013-2024Figure 4.16 Alprolix: Revenue Forecast ($m), 2013-2024Figure 4.17 N8-GP: Revenue Forecast ($m), 2013-2024Figure 4.18 N9-GP: Revenue Forecast ($m), 2013-2024Figure 5.1 Leading National Markets for Bleeding Disorders: Market Share (%), 2012Figure 5.2 Leading National Markets for Bleeding Disorders: Market Shares (%), 2018Figure 5.3 Leading National Markets for Bleeding Disorders: Market Share (%), 2024Figure 5.4 The US Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.5 The EU5 Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.6 The German Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.7 The French Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.8 The Italian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.9 The UK Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.10 The Spanish Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.11 The Japanese Bleeding Disorders Market: Revenue Forecast ($m) 2013-2024Figure 5.12 The Chinese Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.13 The Brazilian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.14 The Indian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 5.15 The Russian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024Figure 6.1 Overview of R&D Pipeline for Bleeding Disorders: Candidates Filed for Approval or in Phase III Trials, 2013Figure 7.1 Leading Companies of the Bleeding Disorders Market: Market Share (%), 2012Figure 10.1 The World Market for Bleeding Disorders by Disorder: Comparison of Revenues ($m), 2012-2024Figure 10.2 Leading Drugs of the Bleeding Disorders Market: Comparison of Revenues ($m), 2012, 2018 and 2024Figure 10.3 Leading National Markets for Bleeding Disorders: Comparison of Revenues ($m), 2012, 2018 and 2024

Companies Listed

AmgenAryoGen BiopharmaAsklepios BiopharmaceuticalsBaxterBayerBeijing Northland BiotechBiogen IdecBrazilian Ministry of HealthCanadian Haemophilia SocietyCangene CorporationCatalyst BiosciencesChatham TherapeuticsCSL BehringEisaiEmpresa Brasileira de Hemoderivadose BiotechnologiaEuropean Medicines Agency (EMA)Food and Drug Administration (US FDA)Genetics InstituteGlaxoSmithKline (GSK)Green Cross CorporationGrifols BiologicalsHaemophilia Centres of England, Scotland, Northern Ireland or WalesHaemophilia Treatment Centre Collaborative Network of China (HTCCNC)HaemophilialifeHemobrásInspiration BiopharmaceuticalsIpsen PharmaItalian Association of Haemophilia Centres (AICE)Johns Hopkins MedicineLigand PharmaceuticalsNational Health Service (NHS)National Heart, Lung and Blood InstituteNektar TherapeuticsNovo NordiskOctapharmaPfizerShenyang Sunshine Pharmaceutical Co.Spanish Haemophilia SocietySwedish Orphan BiovitrumUnited Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO)US Food and Drug Administration (FDA)World Federation of Haemophilia

To order this report: Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024 http://www.reportlinker.com/p02006104/Bleeding-Disorders-World-Pharmaceutical-Industry-and-Market-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In this Women in Technology Power Panel at 15th Cloud Expo, moderated by Anne Plese, Senior Consultant, Cloud Product Marketing at Verizon Enterprise, Esmeralda Swartz, CMO at MetraTech; Evelyn de Souza, Data Privacy and Compliance Strategy Leader at Cisco Systems; Seema Jethani, Director of Product Management at Basho Technologies; Victoria Livschitz, CEO of Qubell Inc.; Anne Hungate, Senior Director of Software Quality at DIRECTV, discussed what path they took to find their spot within the tec...
Can the spatial component of your Big Data be harnessed and visualized, adding another dimension of power and analytics to your data? In his session at Big Data Expo®, John Meza, Product Engineer and Performance Engineering Team Lead at Esri, discussed the spatial queries that can be used within the Hadoop ecosystem and their integration with GeoSpatial applications. The GIS Tools for Hadoop project was also discussed and its implementation to discover location-based patterns and relationships...
The cloud is becoming the de-facto way for enterprises to leverage common infrastructure while innovating and one of the biggest obstacles facing public cloud computing is security. In his session at 15th Cloud Expo, Jeff Aliber, a global marketing executive at Verizon, discussed how the best place for web security is in the cloud. Benefits include: Functions as the first layer of defense Easy operation –CNAME change Implement an integrated solution Best architecture for addressing network-l...
Today, IT is not just a cost center. IT is an enabler and driver of business. With the emergence of the hybrid cloud paradigm, IT now has increasingly more capabilities to create new strategic opportunities for a business. Hybrid cloud allows an organization to utilize multi-tenant public clouds, dedicated private clouds, bare metal hosting, and the associated support and services for the right use cases through an on-demand, XaaS model. This model of IT creates tremendous opportunities for busi...
Wearable devices have come of age. The primary applications of wearables so far have been "the Quantified Self" or the tracking of one's fitness and health status. We propose the evolution of wearables into social and emotional communication devices. Our BE(tm) sensor uses light to visualize the skin conductance response. Our sensors are very inexpensive and can be massively distributed to audiences or groups of any size, in order to gauge reactions to performances, video, or any kind of present...
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete...
Amazon, Google and Facebook are household names in part because of their mastery of Big Data. But what about organizations without billions of dollars to spend on Big Data tools - how can they extract value from their data? In his session at 6th Big Data Expo®, Ali Ghodsi, Co-Founder and Head of Engineering at Databricks, discussed how the zero management cost and scalability of the cloud is addressing the challenges and pain points that data engineers face when working with Big Data. He also s...
In this scenarios approach Joe Thykattil, Technology Architect & Sales at TimeWarner / Navisite, presented examples that will allow business-savvy professionals to make informed decisions based on a sound business model. This model covered the technology options in detail as well as a financial analysis. The TCO (Total Cost of Ownership) and ROI (Return on Investment) demonstrated how to start, develop and formulate a business case that will allow both small and large scale projects to achieve...
IBM has announced a new strategic technology services agreement with Anthem, Inc., a health benefits company in the U.S. IBM has been selected to provide operational services for Anthem's mainframe and data center server and storage infrastructure for the next five years. Among the benefits of the relationship, Anthem has the ability to leverage IBM Cloud solutions that will help increase the ease, availability and speed of adding infrastructure to support new business requirements.
Almost everyone sees the potential of Internet of Things but how can businesses truly unlock that potential. The key will be in the ability to discover business insight in the midst of an ocean of Big Data generated from billions of embedded devices via Systems of Discover. Businesses will also need to ensure that they can sustain that insight by leveraging the cloud for global reach, scale and elasticity.
Cloud computing started a technology revolution; now DevOps is driving that revolution forward. By enabling new approaches to service delivery, cloud and DevOps together are delivering even greater speed, agility, and efficiency. No wonder leading innovators are adopting DevOps and cloud together! In his session at DevOps Summit, Andi Mann, Vice President of Strategic Solutions at CA Technologies, explored the synergies in these two approaches, with practical tips, techniques, research data, wa...
Software AG and Wipro Ltd. have announced a joint solution platform for streaming analytics that provides real-time actionable intelligence for the Internet of Things (IoT) market. “The key to successfully addressing the IoT market is the ability to rapidly build and evolve apps that tap into, analyze and make smart decisions on fast, big data”, said John Bates, Global Head of Industry Solutions and CMO, Software AG. To address the huge market potential created by streaming analytics in conj...
Appcore deploys cloud for service providers based on the Apache Cloud set. In this demo at 15th Cloud Expo, Nate Gordon, Director of Technology at Appcore, shows their new product that's coming out in January - Appcore Atlas, which is focused on deploying private clouds based on CloudStack in 15 minutes or less. Our upcoming June 9-11, 2015, event in New York City will present a total of 10 simultaneous tracks (the largest conference content in the world) by an all-star faculty, over three days...
The term culture has had a polarizing effect among DevOps supporters. Some propose that culture change is critical for success with DevOps, but are remiss to define culture. Some talk about a DevOps culture but then reference activities that could lead to culture change and there are those that talk about culture change as a set of behaviors that need to be adopted by those in IT. There is no question that businesses successful in adopting a DevOps mindset have seen departmental culture change, ...
“With easy-to-use SDKs for Atmel’s platforms, IoT developers can now reap the benefits of realtime communication, and bypass the security pitfalls and configuration complexities that put IoT deployments at risk,” said Todd Greene, founder & CEO of PubNub. PubNub will team with Atmel at CES 2015 to launch full SDK support for Atmel’s MCU, MPU, and Wireless SoC platforms. Atmel developers now have access to PubNub’s secure Publish/Subscribe messaging with guaranteed ¼ second latencies across PubN...